UG Healthcare Corp. Ltd. (8K7) AI Stock Analysis

• Market Cap: S$49.28M
• Dividend Yield: N/A
• Average Volume (3M): 131.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.84
• Revenue Growth: 25.06%
• EPS Growth: 37.11%
• Country: SG
• Employees: 898
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): >-0.01
• Shares Outstanding: 623,825,800
• 10 Day Avg. Volume: 276,890
• 30 Day Avg. Volume: 131,003
• PEG Ratio: 0.48
• Price to Book (P/B): 0.43
• Price to Sales (P/S): 0.47
• P/FCF Ratio: -8.39
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: S$0.08 ▼(-21.00% Downside)
• Action: Upgraded Date: 01/28/26
• Date: Action: Upgraded 01/28/26

The score is primarily held back by weak profitability and deteriorating cash flow despite strong revenue growth, with only partial support from a relatively stable balance sheet. Technicals are moderately positive with price above major moving averages, but valuation is constrained by a negative P/E and lack of dividend data.

Positive Factors

High revenue growth

Reported 51.77% revenue growth signals durable demand expansion and successful market penetration. Sustained top-line expansion provides scope to absorb fixed costs, build scale, and support reinvestment in capacity and distribution, improving medium-term operating leverage if cost control continues.

Conservative leverage and strong equity base

A debt-to-equity of 0.30 and equity ratio of 68.33% indicate a solid capital structure with moderate leverage. This financial flexibility supports working capital needs, capacity investment and buffers versus industry shocks, reducing refinancing risk and enhancing resilience over the next several quarters.

Integrated manufacturing & distribution of essential PPE

Vertical integration across manufacturing and distribution of single-use gloves and PPE provides control over supply, quality and margins. Serving healthcare and industrial channels with owned brands and distribution gives diversified end-markets and stable structural demand for infection-prevention products.

Negative Factors

Negative profitability margins

Negative net and EBIT margins show the company is not converting sales into sustainable profits. Persistent margin weakness limits retained earnings, constrains reinvestment capacity and indicates structural cost or pricing issues that must be addressed to restore durable profitability.

Deteriorating cash generation

A -78.07% free cash flow decline and negative operating cash flow-to-income ratio denote weakening cash conversion. Reduced cash generation limits ability to fund capex, service obligations or grow organically, increasing reliance on external funding and elevating liquidity risk over the medium term.

Negative return on equity

ROE of -2.39% indicates shareholder capital is delivering negative returns, reflecting operational underperformance or inefficient capital deployment. Sustained negative ROE can erode equity value, make capital raising harder and constrain strategic investments across the next several quarters.

UG Healthcare Corp. Ltd. Business Overview & Revenue Model

Company Description

UG Healthcare Corp. Ltd. (8K7) is a prominent player in the healthcare sector, primarily focused on the manufacturing and distribution of medical gloves and other healthcare-related products. The company operates in various markets, providing essential products to hospitals, clinics, and healthcare providers worldwide. With a commitment to quality and innovation, UG Healthcare has established a strong reputation for its nitrile and latex gloves, catering to both the medical and industrial sectors.

How the Company Makes Money

UG Healthcare makes money primarily by selling disposable gloves and other protective healthcare products to customers such as hospitals, clinics, distributors, and industrial/end-user segments, depending on market demand. Revenue is generated from (i) manufacturing and sale of gloves (typically nitrile and/or latex, subject to the company’s product mix) under its own brands and/or as supplier to third parties, and (ii) distribution of third-party healthcare and protective products where the company acts as a reseller/marketing and distribution partner. Earnings are influenced by volume sold and average selling prices for gloves, which tend to fluctuate with global supply-demand conditions, raw material input costs, and freight/logistics costs. Information on specific major customers, contractual structures (e.g., long-term offtake agreements), and named strategic partnerships is null.

UG Healthcare Corp. Ltd. Financial Statement Overview

Summary

Strong revenue growth (51.77%) is outweighed by weak profitability (net margin -2.63%, EBIT margin -0.87%) and pressured cash generation (free cash flow growth -78.07% and negative operating cash flow to net income ratio). Balance sheet is comparatively steadier with moderate leverage (debt-to-equity 0.30) and a strong equity base (equity ratio 68.33%), but negative ROE (-2.39%) remains a concern.

Income Statement

UG Healthcare Corp. Ltd. has experienced significant revenue growth of 51.77% in the latest year, indicating strong sales performance. However, the company is facing profitability challenges, with a negative net profit margin of -2.63% and an EBIT margin of -0.87%. This suggests that despite increasing revenues, the company is struggling to convert sales into profits, potentially due to high operating costs or other inefficiencies.

Balance Sheet

The company's debt-to-equity ratio of 0.30 indicates a moderate level of leverage, which is relatively stable compared to previous years. However, the return on equity is negative at -2.39%, reflecting the company's inability to generate positive returns for shareholders. The equity ratio stands at 68.33%, suggesting a strong equity base relative to total assets, which provides some financial stability.

Cash Flow

UG Healthcare Corp. Ltd. has a negative free cash flow growth rate of -78.07%, indicating a significant decline in cash generation. The operating cash flow to net income ratio is negative, highlighting cash flow challenges. However, the free cash flow to net income ratio of 1.70 suggests that the company is generating more free cash flow relative to its net income, which could be a positive sign if sustained.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	94.93M	144.07M	115.20M	101.13M	232.60M	338.40M
Gross Profit	3.43M	34.74M	25.87M	1.45M	84.39M	196.16M
EBITDA	-21.20M	2.47M	-3.94M	-23.97M	53.37M	163.04M
Net Income	-20.93M	-3.79M	-6.06M	-20.73M	36.80M	118.77M
Balance Sheet
Total Assets	215.39M	232.35M	226.45M	230.00M	288.04M	268.29M
Cash, Cash Equivalents and Short-Term Investments	45.13M	23.29M	28.00M	61.74M	100.22M	68.44M
Total Debt	28.46M	47.36M	43.72M	31.13M	17.98M	16.74M
Total Liabilities	44.08M	76.03M	65.17M	48.81M	52.98M	73.53M
Stockholders Equity	171.94M	158.73M	163.39M	180.84M	228.90M	190.64M
Cash Flow
Free Cash Flow	-36.98M	-8.11M	-20.71M	-47.17M	31.63M	61.47M
Operating Cash Flow	-34.35M	-4.78M	-18.16M	-39.14M	53.95M	81.16M
Investing Cash Flow	-2.63M	-3.21M	-22.73M	-8.03M	-21.19M	-18.89M
Financing Cash Flow	4.62M	3.24M	8.36M	8.70M	-973.00K	-3.14M

UG Healthcare Corp. Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:8K7, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.09, and below the 200-day MA of 0.10, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 23.44 is Positive, neither overbought nor oversold. The STOCH value of 43.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:8K7.

UG Healthcare Corp. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AP4	74 Outperform	S$1.10B	22.00	13.18%	8.70%	4.74%	-17.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
8K7	49 Neutral	S$49.28M	―	-2.36%	―	25.06%	37.11%